Goldman Sachs Group Inc Analysts Give Sanofi SA (SAN) a €82.00 Price Target
Sanofi SA (EPA:SAN) has been given a €82.00 ($92.13) target price by analysts at Goldman Sachs Group Inc in a research note issued to investors on Wednesday. The firm currently has a “neutral” rating on the stock.
Several other research firms have also weighed in on SAN. Jefferies Group LLC set a €87.00 ($97.75) price objective on shares of Sanofi SA and gave the stock a “neutral” rating in a report on Thursday, March 9th. Deutsche Bank AG set a €96.00 ($107.87) price objective on shares of Sanofi SA and gave the stock a “buy” rating in a report on Thursday, February 9th. HSBC Holdings plc set a €77.00 ($86.52) price objective on shares of Sanofi SA and gave the stock a “sell” rating in a report on Friday, April 7th. Berenberg Bank set a €97.00 ($108.99) price objective on shares of Sanofi SA and gave the stock a “neutral” rating in a report on Saturday. Finally, Barclays PLC set a €70.00 ($78.65) price objective on shares of Sanofi SA and gave the stock a “sell” rating in a report on Wednesday, March 8th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of €86.44 ($97.12).
Sanofi SA (EPA:SAN) opened at 87.85 on Wednesday. The stock’s 50 day moving average price is €25.48 and its 200 day moving average price is €25.74. Sanofi SA has a 12 month low of €62.50 and a 12 month high of €92.97.
COPYRIGHT VIOLATION NOTICE: “Goldman Sachs Group Inc Analysts Give Sanofi SA (SAN) a €82.00 Price Target” was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/05/24/goldman-sachs-group-inc-analysts-give-sanofi-sa-san-a-82-00-price-target.html.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.